Pharmacology of GYKI - 41 099 ( chlorpropanol , Tobanum ) a new potent beta - adrenergic antagonist .
The compound GYKI - 41 099 , as a beta - adrenergic antagonist , is 3 - 8 times more potent than propranolol in vitro and in vivo .
Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats .
GYKI - 41 900 has a negligible cardiodepressant activity ; it is not cardioselective .
The compound shows a rapid and long lasting effect .
There was a prolonged elimination of the radioactivity after the injection of 14C - 41 099 to rats and dogs .
The half life of the unlabeled substance in humans was more than 10 hours .